Drugs / BI 1323495
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04656275 | Mar → Dec 2021 | bronchiectasis | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT04619251 | Nov 2020 → Jul 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04257032 | Feb → Sep 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04107805 | Nov 2019 → Mar 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04011241 | Jul → Sep 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03802331 | Jan → Mar 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03588390 | Jul → Nov 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1323495 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04257032 ↗ |
| Route | Oral | “following oral administration” NCT03588390 ↗ |